A study determined that barzolvolimab was not a primary driver in the treatment of Eosinophilic Esophagitis.
1 report, 1 independent
Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A study determined that barzolvolimab was not a primary driver in the treatment of Eosinophilic Esophagitis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Celldex Therapeutics
American biopharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireCelldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the ga